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Background and Aims: We measured the effectiveness of 23-valent pneumococcal polysaccharidic 
vaccine (PPV23) against invasive pneumococcal disease (IPD) in 65+ year-olds, pooling surveillance 
data from seven European sites. PPV23 vaccination is recommended in all sites (8-69% uptake) and 
PCV13 in high risk groups in two sites (<5% uptake). Methods: We compared the vaccination status 
of IPD cases caused by PPV23 serotypes (cases) to that of nonPPV23 IPD (controls) notified between 
2012 and 2016. We defined PPV23 vaccination as at least one dose. PPV23 pooled effectiveness was 
calculated as (1 ʹodds ratio of vaccination)*100, adjusted for site, age, sex, underlying conditions 
and year. We stratified PPV23 effectiveness by time since last dose of vaccine: <2, 2-4, 5-9 and 10+ 
years. Results: We included 2011 cases and 878 controls. Compared to controls, cases were younger 
(p=0.001), less likely to have an underlying condition (p=0.025), more likely to be admitted for 
intensive care (p=0.038) and to have pneumonia (p=0.005). PPV23 effectiveness was 24% (95%CI: 4; 
41) against PPV23-serotypes. By serotype, PPV23 effectiveness ranged between -2% (95%CI: -48; 30) 
against serotype 3 (n=687) and 55% (95%CI: 15; 76) against serotype 9N IPD (n=540). By years since 
vaccination, PPV23 effectiveness was 43% (95%CI: 3-66) and 15% (95%CI: -25; 43) for <2 years and 
10+ years, respectively. Conclusion: Our findings suggest a low PPV23 effectiveness against IPD 
caused by PPV23 serotypes in the elderly, varying by serotype, and higher in the first two years after 
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